NanoViricides Says The Healthy Subjects Part Of The Phase 1a/1b Clinical Trial Of NV-CoV-2 Was Completed Successfully And No Adverse Events Were Reported In Any Of The Ascending Dose Cohorts
NanoViricides Says The Healthy Subjects Part Of The Phase 1a/1b Clinical Trial Of NV-CoV-2 Was Completed Successfully And No Adverse Events Were Reported In Any Of The Ascending Dose Cohorts
nanoviricides表示，NV-CoV-2的1a/1b期临床试验的健康受试者部分已成功完成，在任何剂量上升的队列中均未报告任何不良事件
NanoViricides Says The Healthy Subjects Part Of The Phase 1a/1b Clinical Trial Of NV-CoV-2 Was Completed Successfully And No Adverse Events Were Reported In Any Of The Ascending Dose Cohorts
nanoviricides表示，NV-CoV-2的1a/1b期临床试验的健康受试者部分已成功完成，在任何剂量上升的队列中均未报告任何不良事件
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。